Cereno Scientific submits application for the start of clinical Phase II study
Cereno Scientific has today submitted its application for clinical trial to the Russian authorities regarding the company’s Phase II study with the drug candidate CS1. The company intends to start the study during the first half of 2020. Soon, an application will also be submitted to the authorities in Bulgaria.“It is pleasing that all the hard work together with our partners has resulted in us being able to submit the application during the second quarter this year instead of during the third quarter which was the initial plan,” says Cereno Scientific’s CEO Sten R. Sörensen. The aim of